CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published ahead of print on April 5, 2006
Clin J Am Soc Nephrol 1: 525-531, 2006
© 2006 American Society of Nephrology
doi: 10.2215/CJN.01391005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.01391005v1
1/3/525    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arakawa, T.
Right arrow Articles by Fukagawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arakawa, T.
Right arrow Articles by Fukagawa, M.

Mineral Metabolism and Bone Disease

Overproduction and Secretion of a Novel Amino-Terminal Form of Parathyroid Hormone from a Severe Type of Parathyroid Hyperplasia in Uremia

Toshio Arakawa*,{dagger}, Pierre D’Amour{ddagger}, Louise Rousseau{ddagger}, Jean-Hugues Brossard{ddagger}, Makoto Sakai§, Hiroomi Kasumoto§, Naoya Igaki§, Takeo Goto§, Tom Cantor||, and Masafumi Fukagawa*

* Division of Nephrology & Dialysis Center, Kobe University School of Medicine, Kobe, Japan; {dagger} Arakawa Renal Clinic, Takasago, Japan; {ddagger} Centre de recherche, Centre hospitalier de l’Université de Montréal, Hôpital Saint-Luc, and Département de médecine, Université de Montréal, Montréal, Québec, Canada; § Department of Internal Medicine, Takasago Municipal Hospital, Takasago, Japan; and || Scantibodies Laboratory Inc., Santee, California

Address correspondence to: Dr. Masafumi Fukagawa, Division of Nephrology & Dialysis Center, Kobe University School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017 Japan. Phone: +81-78-382-6500; Fax: +81-78-382-6509; fukagawa{at}med.kobe-u.ac.jp

Measurement of bioactive parathyroid hormone (PTH) is essential for optimal management of bone abnormalities in dialysis patients. This can be accomplished by PTH measurements using third-generation PTH assays, which detect more or less of the first six amino acids of the PTH structure. Such assays do not detect non-(1-84) PTH fragments, such as human PTH (7-84), which are recognized by the second-generation PTH assays that use a detection antibody that recognizes an epitope within the 13-34 region of the PTH structure. Therefore, third-generation PTH results are expected to be lower than those that are obtained with second-generation PTH assays. Rare exceptions to this rule have been reported for patients with severe primary hyperparathyroidism or parathyroid cancer. Sera and gland extracts were analyzed from a dialysis patient with high bone turnover disease and with surprising higher PTH levels by a third-generation assay than by a second-generation assay. This finding normalized after the surgical removal of an enlarged gland with a single nodule, an advanced type of nodular hyperplasia. HPLC fractionation of sera and gland extracts revealed the overproduction and secretion of a PTH molecule with an intact amino-terminus structure distinct from (1-84) PTH. This form of PTH was readily detectable by third-generation PTH assays but was poorly reactive in second-generation PTH assays. Therefore, parathyroid glands with advanced uremic nodular hyperplasia may overproduce and secrete a novel, biologically active form of PTH with an intact 1-6 region but a presumably modified 12-18 region required for the detection in second-generation PTH assays.




This article has been cited by other articles:


Home page
NDT PlusHome page
H. Komaba, Y. Takeda, J. Shin, R. Tanaka, T. Kakuta, Y. Tominaga, and M. Fukagawa
Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
NDT Plus, August 1, 2008; 1(suppl_3): iii54 - iii58.
[Abstract] [Full Text] [PDF]


Home page
NDT PlusHome page
M. Tanaka, H. Komaba, K. Itoh, K. Matsushita, K. Matshushita, Y. Hamada, H. Fujii, and M. Fukagawa
The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism
NDT Plus, August 1, 2008; 1(suppl_3): iii59 - iii62.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
H. Komaba, Y. Takeda, T. Abe, K. Komaba, N. Otsuki, K.-i. Nibu, M. Umezu, and M. Fukagawa
Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient
Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1760 - 1762.
[Full Text] [PDF]


Home page
CJASNHome page
T. B. Drueke and M. Fukagawa
Whole or Fragmentary Information on Parathyroid Hormone?
Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1106 - 1107.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Nephrology.